San Clemente, CA, United States of America

Xialing Guo

USPTO Granted Patents = 21 (Patent Applications = 3)

CIPO Patents = 1

EPO Patents = 3 (Patent Applications = 2)

Average Co-Inventor Count = 3.1

ph-index = 5

Forward Citations = 114(Granted Patents)

Location History:

Irvine, CA (US) (2003 - 2009)
San Clemente, CA (US) (2011 - 2019)

Company Filing History:

Years Active: 2003-2019

Loading Chart...

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10221192 - Compounds as tyrosine kinase modulators (2019-03-05),

2. 9758509 - Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors (2017-09-12),

3. 9725433 - Compounds as tyrosine kinase modulators (2017-08-08),

4. 9657005 - Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors (2017-05-23),

5. 9475801 - Compounds as tyrosine kinase modulators (2016-10-25),

6. 9340555 - Compounds as tyrosine kinase modulators (2016-05-17),

7. 9328103 - Compounds as tyrosine kinase modulators (2016-05-03),

8. 8906944 - Compounds as tyrosine kinase modulators (2014-12-09),

9. 8877923 - Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-ones and derivatives thereof as kinase inhibitors (2014-11-04),

10. 8865682 - Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors (2014-10-21),

11. 8809534 - Compounds as tyrosine kinase modulators (2014-08-19),

12. 8614234 - Compounds as tyrosine kinase modulators (2013-12-24),

13. 8455656 - Kinase inhibitors (2013-06-04),

14. 8455535 - Heteroaryl dihydroindolones as kinase inhibitors (2013-06-04),

15. 8367664 - Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors (2013-02-05),

Title: Innovations in Tyrosine Kinase Modulation by Xialing Guo

Introduction: Xialing Guo is a prominent inventor based in San Clemente, CA, known for his noteworthy contributions in the field of pharmaceuticals, particularly in the development of compounds that act as tyrosine kinase modulators. With 21 patents to his name, Guo has made significant strides in the medical research landscape, paving the way for innovative treatment methods.

Latest Patents: Among his recent patents, Guo has focused on two key inventions. The first patent involves novel compounds designed to act as potent tyrosine kinase modulators, aimed at treating and preventing various diseases linked to the abnormal activity of tyrosine kinase receptors. The second patent presents organic molecules capable of effectively modulating tyrosine kinase signal transduction, thereby regulating abnormal cell proliferation. These inventions have the potential to offer new therapeutic options in oncology and other related fields.

Career Highlights: Throughout his career, Xialing Guo has collaborated with notable firms in the pharmaceutical industry, including Allergan Inc. and Allergan Sales Inc. His experience with these companies has significantly influenced his research and development efforts, leading to impactful innovations in drug development.

Collaborations: In his professional journey, Guo has worked alongside talented individuals such as Zhen Zhu and Thomas C. Malone. These collaborations have enabled him to leverage collective expertise and foster an innovative environment, enhancing the success of his projects.

Conclusion: Xialing Guo stands out as a leading inventor in the field of tyrosine kinase modulation, with a robust portfolio of patents highlighting his contributions. His ongoing research and collaborative efforts continue to inspire advancements in medical science, reflecting a commitment to developing solutions for complex health challenges.

This text is generated by artificial intelligence and may not be accurate.